Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prostate-specific antigen-all that rises is not refractory.

B L Hintz1, A Van Nieuwenhuize, A R Kagan

  • 1Department of Radiation Oncology, Southern California Permanente Medical Group, Los Angeles, California, USA.

Urology
|May 19, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of radiation therapy in children with acute lymphoblastic leukemia kidney infiltration.

Medical and pediatric oncology·2001
Same author

Serum PSA evaluations during salvage radiotherapy for post-prostatectomy biochemical failures as prognosticators for treatment outcomes.

International journal of radiation oncology, biology, physics·2001
Same author

Spinal cord compression, infection, and unknown primary cancers.

American journal of clinical oncology·2001
Same author

High-grade carcinoma of the prostate: a comparison of current local therapies.

Urology·2001
Same author

Back to the future: reexploring radiotherapy for benign disease.

Frontiers of radiation therapy and oncology·2001
Same author

The American Cancer Center.

American journal of clinical oncology·2001

A rising prostate-specific antigen (PSA) in prostate cancer patients on androgen suppression can indicate treatment resistance. This case shows a patient whose PSA declined with bicalutamide despite initial resistance.

Area of Science:

  • Oncology
  • Endocrinology

Background:

  • Androgen suppression therapy is a standard treatment for prostate cancer.
  • Serum prostate-specific antigen (PSA) levels typically decrease with androgen suppression.
  • A rise in PSA during treatment often suggests the development of hormone-refractory prostate cancer.

Observation:

  • A patient receiving depot leuprolide for prostate cancer experienced an increase in PSA levels.
  • This patient also presented with elevated testosterone levels, which is unusual during androgen suppression therapy.

Findings:

  • The patient's rising PSA and testosterone levels initially suggested treatment resistance.
  • However, subsequent administration of bicalutamide led to a decline in PSA levels.

Implications:

Related Experiment Videos

  • This case highlights a potential alternative treatment response in advanced prostate cancer.
  • It suggests that bicalutamide may be effective even when initial androgen suppression appears to fail.
  • Further investigation into such paradoxical responses could refine treatment strategies for hormone-refractory prostate cancer.